Gufic Biosciences vs Indoco Remedies: Fair Value & Quality
Both stocks run through our valuation models. Here is how Gufic Biosciences (509079) and Indoco Remedies (INDOCO) compare, as of Aug 15, 2026.
As of Aug 15, 2026, Fair Value Calculator sees Indoco Remedies as the less overvalued of the two: Gufic Biosciences trades at ₹421 versus a fair value of ₹182 (-57%), while Indoco Remedies trades at ₹220 versus ₹101 (-54%).
Gufic Biosciences
509079.BSE · INR · Health Care
-57%
upside to fair value
overvalued
Price₹421
Fair Value₹182
Quality48/100
Indoco Remedies
INDOCO.NSE · INR · Health Care
-54%
upside to fair value
overvalued
Price₹220
Fair Value₹101
Quality36/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Gufic BiosciencesIndoco Remedies
Valuation
77.1×P/E (TTM)—
1.96×P/S (TTM)0.01×
1.16×P/B—
18.1×EV/EBITDA3.6×
0.0%Dividend yield0.1%
₹0.05Dividend per share₹0.20
Profitability
7%Net margin-5%
11%Operating margin4%
25%Return on equity-10%
7%Return on assets0%
Growth
43%Revenue growth (YoY)22%
1.7%Avg. growth/yr (3Y)4.0%
18.0%Avg. growth/yr (5Y)8.7%
Balance & size
0.22×Debt / equity0.55×
$73MMarket cap$236M
healthyGrowth qualityexpensive
Gufic Biosciences leads: 7 to 4 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Gufic Biosciencesof which business quality 48 · market factors 64Indoco Remediesof which business quality 36 · market factors 42
ProfitabilityMargins and returns on capital today
49
21
Quality GrowthAre margins and returns improving?
39
57
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
20
62
Low VolatilityCalm price path (market factor)
50
64
MomentumPrice trend over the last 3–12 months (market factor)
72
41
52W MomentumDistance to the 52-week high (market factor)
65
19
Net IssuanceBuybacks instead of dilution
76
68
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Gufic Biosciences
DCF Models₹218
Earnings-Based₹148
Dividend Discount₹2.10
Multiples₹189
Asset-Based₹51.74
Growth DCF₹184
Economic Profit₹133
Growth Earnings₹221
26 of 26 models see the stock below the current price.
Indoco Remedies
Dividend Discount₹3.65
Multiples₹163
Asset-Based₹68.28
4 of 4 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Gufic Biosciences
Bear ₹81.58Fair Value ₹182Bull ₹246
₹421 = current price (white tick)
Indoco Remedies
Bear ₹46.88Fair Value ₹101Bull ₹155
₹220 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Gufic Biosciences · Health Care
Quality score48 · below median
Fair value upside-57% · below median
Indoco Remedies · Health Care
Quality score36 · bottom 25%
Fair value upside-54% · below median
Bottom line
As of Aug 15, 2026, Fair Value Calculator sees Indoco Remedies as the less overvalued of the two: Gufic Biosciences trades at ₹421 versus a fair value of ₹182 (-57%), while Indoco Remedies trades at ₹220 versus ₹101 (-54%).
Gufic Biosciences has the higher quality score (48/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
